We are live on
!
Find out more
VIA
Vident Investment Advisory Portfolio holdings
AUM
$2.9B
1-Year Est. Return
24.67%
This Fund
S&P 500
This Quarter
Est. Return
+6.67%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$824M
AUM Growth
+$71.1M
(+9.4%)
Cap. Flow
+$34.5M
Cap. Flow
% of AUM
4.19%
Top 10 Holdings %
Top 10 Hldgs %
11.01%
Holding
412
New
24
Increased
206
Reduced
148
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$30.7M |
| 2 |
Qualcomm
QCOM
|
+$1.51M |
| 3 |
Howmet Aerospace
HWM
|
+$1.4M |
| 4 |
RAVN
Raven Industries Inc
RAVN
|
+$1.06M |
| 5 |
HOLI
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
|
+$921K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RAX
Rackspace Hosting Inc
RAX
|
+$3.13M |
| 2 |
BRCD
Brocade Communications Systems, Inc. NEW
BRCD
|
+$2.34M |
| 3 |
IM
Ingram Micro
IM
|
+$2.33M |
| 4 |
JOY
Joy Global Inc
JOY
|
+$2.25M |
| 5 |
Southwest Gas
SWX
|
+$2.17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.33% |
| 2 | Financials | 11.1% |
| 3 | Healthcare | 10.59% |
| 4 | Industrials | 9.77% |
| 5 | Consumer Discretionary | 9.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Novartis
NVS
$297B
| $762K | 0.09% |
11,679
+1,848
| +19% | +$120K |
|
302
Xencor
XNCR
$1.55B
| $759K | 0.09% |
28,856
-19,060
| -40% | -$458K |
|
|
ONC
303
BeOne Medicines Ltd
ONC
$39.4B
| $758K | 0.09% |
24,958
+2,207
| +10% | +$69.4K |
|
|
KDNY
304
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $751K | 0.09% |
13,175
+1,577
| +14% | +$95.4K |
|
|
JUNO
305
DELISTED
Juno Therapeutics, Inc.
JUNO
| $744K | 0.09% |
39,480
+23,704
| +150% | +$580K |
|
306
Bristol-Myers Squibb
BMY
$132B
| $740K | 0.09% |
12,660
+2,823
| +29% | +$154K |
|
307
Inovio Pharmaceuticals
INO
$69M
| $737K | 0.09% |
8,846
+3,564
| +67% | +$322K |
|
308
AstraZeneca
AZN
$250B
| $728K | 0.09% |
13,329
+1,072
| +9% | +$60.9K |
|
309
Comcast
CMCSA
$90B
| $727K | 0.09% |
21,044
+5,910
| +39% | +$197K |
|
310
Iovance Biotherapeutics
IOVA
$2.87B
| $727K | 0.09% |
104,616
+17,220
| +20% | +$118K |
|
|
CLLS
311
Cellectis
CLLS
$285M
| $720K | 0.09% |
42,498
+17,244
| +68% | +$319K |
|
312
PayPal
PYPL
$50.5B
| $700K | 0.09% |
+17,726
| New | +$712K |
|
313
Celldex Therapeutics
CLDX
$3.28B
| $696K | 0.08% |
13,114
+2,875
| +28% | +$164K |
|
|
SRNE
314
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $696K | 0.08% |
+142,114
| New | +$854K |
|
|
AGEN
315
Agenus
AGEN
$290M
| $695K | 0.08% |
8,596
+54
| +0.6% | +$5.3K |
|
316
CytomX Therapeutics
CTMX
$754M
| $695K | 0.08% |
63,272
-4,124
| -6% | -$50K |
|
|
LUMO
317
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $691K | 0.08% |
7,468
+415
| +6% | +$46.8K |
|
|
KITE
318
DELISTED
Kite Pharma, Inc.
KITE
| $671K | 0.08% |
14,968
+2,064
| +16% | +$101K |
|
319
Alcoa
AA
$13.2B
| $669K | 0.08% |
+23,808
| New | +$646K |
|
320
ImmunityBio
IBRX
$8.1B
| $661K | 0.08% |
115,579
+13,732
| +13% | +$91.6K |
|
321
Atara Biotherapeutics
ATRA
$76.1M
| $659K | 0.08% |
1,856
+547
| +42% | +$232K |
|
|
YHOO
322
DELISTED
Yahoo Inc
YHOO
| $656K | 0.08% |
16,960
-5,984
| -26% | -$245K |
|
|
ADXS
323
DELISTED
Advaxis Inc
ADXS
| $650K | 0.08% |
6,052
+664
| +12% | +$89.6K |
|
|
BLCM
324
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $642K | 0.08% |
4,716
-607
| -11% | -$108K |
|
|
BLUE
325
DELISTED
bluebird bio
BLUE
| $641K | 0.08% |
802
-473
| -37% | -$376K |
|
Similar funds
EST
TCM
AWS
WI
JP
VCM
FCB
FCFS
Vident Investment Advisory's Q4 2016 Portfolio in Review
As of Q4 2016, Vident Investment Advisory held 412 positions worth $824M, up 9.4% from $753M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Vident Investment Advisory deployed $34.5M of net new capital in Q4 2016, opening 24 new positions and adding to 206 existing holdings. Its largest new stake was Qualcomm: 22,530 shares worth $1.47M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $1.91M trimmed.
- Vident Investment Advisory's largest Q4 2016 buy was Qualcomm: 22,530 shares worth $1.47M.
- Vident Investment Advisory added most to State Street SPDR S&P 500 ETF Trust in Q4 2016, an estimated $30.7M increase.
- Vident Investment Advisory's biggest Q4 2016 reduction was Johnson & Johnson, cutting an estimated $1.91M.
- Vident Investment Advisory fully exited Rackspace Hosting Inc in Q4 2016, selling an estimated $3.13M.
- Vident Investment Advisory's ten largest holdings make up 11% of its $824M portfolio in Q4 2016.
- Vident Investment Advisory opened 24 new positions and closed 33 in Q4 2016.
- Vident Investment Advisory's portfolio value rose 9.4% quarter-over-quarter to $824M.
Based on Vident Investment Advisory's 13F filing for Q4 2016, filed 14 Feb 2017.